Frankfurt - Delayed Quote EUR

Atrys Health, S.A. (A2T.F)

2.7400 -0.0100 (-0.36%)
As of 9:59 AM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
201,569.0000
201,569.0000
158,366.0000
121,014.0000
31,396.0000
Cost of Revenue
59,799.0000
59,799.0000
32,366.0000
20,121.0000
7,146.0000
Gross Profit
141,770.0000
141,770.0000
126,000.0000
100,893.0000
24,250.0000
Operating Expense
136,275.0000
136,275.0000
129,572.0000
113,285.0000
26,387.0000
Operating Income
5,495.0000
5,495.0000
-3,572.0000
-12,392.0000
-2,137.0000
Net Non Operating Interest Income Expense
-32,420.0000
-32,420.0000
-14,230.0000
-9,186.0000
-2,136.0000
Pretax Income
-33,696.0000
-33,696.0000
-26,794.0000
-24,882.0000
-5,381.0000
Tax Provision
-2,941.0000
-2,941.0000
-839.0000
-1,685.0000
167.0000
Net Income Common Stockholders
-45,590.0000
-45,590.0000
-23,147.0000
-23,255.0000
-5,548.0000
Diluted NI Available to Com Stockholders
-45,590.0000
-45,590.0000
-23,147.0000
-23,255.0000
-5,548.0000
Basic EPS
-0.60
--
-0.34
-0.46
-0.20
Diluted EPS
-0.60
--
-0.34
-0.46
-0.20
Basic Average Shares
75,810.5640
--
68,203.8100
50,282.9420
28,315.6180
Diluted Average Shares
77,264.5080
--
70,471.9600
53,519.5280
30,938.9540
Total Operating Income as Reported
-1,844.0000
-1,844.0000
-13,368.0000
-15,014.0000
-230.0000
Rent Expense Supplemental
1,055.0000
1,055.0000
877.0000
997.0000
24.0000
Total Expenses
196,074.0000
196,074.0000
161,938.0000
133,406.0000
33,533.0000
Net Income from Continuing & Discontinued Operation
-45,590.0000
-45,590.0000
-23,147.0000
-23,255.0000
-5,548.0000
Normalized Income
-26,572.5925
-26,572.5925
-18,227.4544
-21,804.0535
-5,419.0000
Interest Income
627.0000
627.0000
304.0000
1,848.0000
210.0000
Interest Expense
33,047.0000
33,047.0000
14,534.0000
5,757.0000
2,346.0000
Net Interest Income
-32,420.0000
-32,420.0000
-14,230.0000
-9,186.0000
-2,136.0000
EBIT
-649.0000
-649.0000
-12,260.0000
-19,125.0000
-3,035.0000
EBITDA
29,024.0000
29,024.0000
13,714.0000
1,663.0000
2,938.0000
Reconciled Cost of Revenue
59,799.0000
59,799.0000
32,366.0000
20,121.0000
7,146.0000
Reconciled Depreciation
29,673.0000
29,673.0000
25,974.0000
20,788.0000
5,973.0000
Net Income from Continuing Operation Net Minority Interest
-30,448.0000
-30,448.0000
-25,697.0000
-23,209.0000
-5,548.0000
Total Unusual Items Excluding Goodwill
-4,246.0000
-4,246.0000
-7,711.0000
-1,507.0000
-172.0000
Total Unusual Items
-4,246.0000
-4,246.0000
-7,711.0000
-1,507.0000
-172.0000
Normalized EBITDA
33,270.0000
33,270.0000
21,425.0000
3,170.0000
3,110.0000
Tax Rate for Calcs
0.0001
0.0001
0.0000
0.0001
0.0003
Tax Effect of Unusual Items
-370.5925
-370.5925
-241.4544
-102.0535
-43.0000
12/31/2020 - 5/5/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NEU.AX Neuren Pharmaceuticals Limited
18.85
-2.33%
 
TARS Tarsus Pharmaceuticals, Inc.
32.76
-2.82%
 
GLPG Galapagos NV
28.77
-2.31%
 
PRTA Prothena Corporation plc
20.56
0.00%
 
MSB.AX Mesoblast Limited
0.9150
+1.67%
 
STRO Sutro Biopharma, Inc.
3.4700
-6.72%
 
INCY Incyte Corporation
51.74
+0.17%
 
SRNEQ Sorrento Therapeutics, Inc.
0.0300
+3.45%
 
MESO Mesoblast Limited
6.22
+3.67%
 
AKBA Akebia Therapeutics, Inc.
1.3700
0.00%